Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-14

Study Completion Date

2018-07-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC). The term 'histologic subtype' refers to how the cells and tumor tissue looks under the microscope. Three different 'histologic subtypes' of basal cell skin cancer (infiltrative/morpheaform, nodular and superficial) will be examined in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

NCT01160250

Basal Cell Carcinoma

APPROVED_FOR_MARKETING

Vismodegib on Locally Advanced Basal Cell Carcinoma Under Real World Conditions

NCT02781389

Basal Cell Carcinoma

COMPLETED

Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas

NCT02639117

Basal Cell Carcinoma

COMPLETED PHASE1

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

NCT01631331

Basal Cell Carcinoma of the Skin Recurrent Skin Cancer

COMPLETED EARLY_PHASE1

To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma

NCT02956889

Carcinoma, Basal Cell

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC). The term 'histologic subtype' refers to how the cells and tumor tissue looks under the microscope. Three different 'histologic subtypes' of basal cell skin cancer (infiltrative/morpheaform, nodular and superficial) will be examined in this study. Each subtype has a characteristic look under the microscope, which is related to how the tumor will behave and grow.

ERIVEDGE (oral vismodegib capsule) has been approved for use in the United States for treatment of metastatic BCC tumors (mBCC), tumors that have spread further into the skin, bones or other tissues, or spread to other parts of the body and locally advanced basal cell skin cancer (laBCC), cancers that have come back after surgery or that the healthcare provider thinks cannot be treated with surgery or radiation. It works by blocking the signal, called Hedgehog, which basal cell skin cancer cells need to grow. It has been given to about 800 people during clinical trials.

Data from previous studies is mostly based on a subtype of BCC made up of little round collections of cancer cells, called "Nodular". There is almost no data on the use of vismodegib in other subtypes of BCC that that tend to extend deep into the skin ("Infiltrative" subtype), or spread widely near the surface of the skin ("Superficial" subtype).

A total of 36 subjects will be enrolled in the study. All study participants will receive oral vismodegib treatment.

At the Week 12 visit, skin biopsies will be performed to give the investigators more information on how the tumor is responding to vismodegib. If there is no evidence of tumor on the biopsy, the subject will be eligible to end treatment early and enter the Observation period. During this time the subject will be followed clinically every 3 months for up to 1 year.

For all other subjects, if any evidence of tumor is seen on biopsy at week 12, the subject will continue treatment for the full 24 weeks. At week 24 visit, skin biopsies will be performed again to see if there is any tumor left. If there is no evidence of tumor on the biopsy, the subject will be eligible to end treatment early and enter the Observation period. If there is tumor left, the subject will be referred for surgery or other standard of care treatment to remove the tumor.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Basal Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Label oral vismodegib

This is a Phase 2B single-site, open-label, nonrandomized 24-week study of the efficacy and safety of vismodegib (150 mg PO daily) in subjects with high risk and/or locally advanced basal cell carcinoma (BCC). A total of 36 subjects with infiltrative/morpheaform, nodular, or superficial BCC will be enrolled in the study.

Group Type EXPERIMENTAL

vismodegib (150 mg PO daily)

Intervention Type DRUG

Biopsies will be performed on all participants at baseline, week 12 and week 24.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vismodegib (150 mg PO daily)

Biopsies will be performed on all participants at baseline, week 12 and week 24.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Brand name: Erivedge

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. A signed and data informed consent
2. Willing to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
3. 18 years of age or older at time of informed consent
4. Have one or more clinically suspicious lesions for BCC at Pre-Study screening Visit that has:

1. a diameter ≥ 6 mm if located on the "mask areas" of face (central face, eyelids, eyebrows, periorbital,nose,lips,chin,mandible,preauricular and postauricular skin/sulci,temple,ear),genitalia,hands,or feet
2. a diameter ≥ 10 mm if located on cheeks,forehead,scalp,or neck
3. a diameter ≥ 20 mm if located on trunk and extremities

or has a lesion suspicious for locally advanced BCC defined as a lesion that:
4. is ≥ 10 mm,
5. has recurred following surgery or surgical resection would result in substantial deformity, and
6. has been deemed not appropriate for radiation.
5. Have a histologically-confirmed BCC prior to first dose of study drug
6. Have an Eastern Cooperative Oncology Group performance status of 2 or less at Baseline
7. Female of reproductive potential must use 2 effective methods to avoid pregnancy during therapy and for 7 months after completing therapy
8. Male patients must use effective measures to avoid pregnancy in their partner at all times during treatment and for 2 months after the last dose
9. Agree not to donate blood or blood products during the study and for 7 months after the last dose
10. Subjects with Basal Cell Nevus Syndrome are eligible for enrollment

Exclusion Criteria

1. Women who are pregnant, lactating, or planning pregnancy while in the study
2. History of prior treatment with vismodegib or any Hh Pathway Inhibitor
3. Evidence of clinically significant and unstable diseases or conditions; Subjects with clinically stable chronic medical conditions will be allowed to enter the study
4. Any dermatological disease at treatment site that the investigator thinks may be exacerbated by treatment with vismodegib or cause difficulty with examination
5. The target lesion identified at Pre-study Screening visit has been determined to be mBCC by radiological assessment prior to first dose of study drug
6. Inability or unwillingness to swallow capsules
7. History of infection requiring hospitalization, IV antimicrobial therapy, or is otherwise judged to be clinically significant by the investigator within 4 wks prior to first dose of study drug
8. History of infection requiring antimicrobial therapy within 2 wks prior to first dose of study drug
9. History of alcohol or substance abuse, unless in full remission for greater than 6 months prior to first dose of study drug
10. Known to be infected with human immunodeficiency virus, hepatitis B or hepatitis C viruses
11. Participation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before the study begins and/or during study participation
12. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results in the judgment of the investigator
13. Subjects who are study site staff members or who are Sponsor employees directly involved in the conduct of the trial
14. A subject who, in the opinion of the investigator or sponsor, will be uncooperative or unable to comply with study procedures

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No